Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWHEV8)

Drug Name
[3H]spiperone Drug Info
Synonyms
Spiperone; spiperone; Spiroperidol; Spiropitan; 749-02-0; Espiperona; Spiperonum; [3H]-spiperone; R 5147; Spiperonum [INN-Latin]; Espiperona [INN-Spanish]; E 525; UNII-4X6E73CJ0Q; NSC 170983; MLS000028615; Spiperone [USAN:INN:BAN:JAN]; 8-(3-(p-Fluorobenzoyl)propyl)-1-phenyl-1,3,8-triazaspiro(45)decan-4-one; 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[45]decan-4-one; 8-(3-p-Fluorobenzoyl-1-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane; EINECS 212-024-0; BRN 0632204; SMR000058674; [3H]-spiperone; SPIPERONE
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5265
ChEBI ID
CHEBI:9233
CAS Number
CAS 749-02-0
TTD Drug ID
DMWHEV8
VARIDT Drug ID
DR01493

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine D3 receptor (D3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cariprazine DMJYDVK Bipolar disorder 6A60 Approved [11]
Pramipexole DMNMW9R Parkinson disease 8A00.0 Approved [12]
Ropinirole DMA6S1D Parkinson disease 8A00.0 Approved [12]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [13]
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [14]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [15]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [16]
TAK-906 DMBQD9H Diabetic gastroparesis DA41.00 Phase 2 [17]
GSK598809 DMGU05N Drug abuse 6C4G.1Z Phase 2 [18]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [19]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [20]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [21]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [22]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [21]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [23]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [24]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [20]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [25]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D4 receptor (D4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [12]
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [27]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [13]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [15]
L-745,870 DMTGR25 Psychotic disorder 6A20-6A25 Phase 2 [28]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [29]
ABT-724 DMDQVY4 Erectile dysfunction HA01.1 Discontinued in Phase 2 [30]
Lu-35138 DMQ7A35 Psychotic disorder 6A20-6A25 Discontinued in Phase 2 [31]
NGD-94-4 DMZ9WLO Schizophrenia 6A20 Discontinued in Phase 1 [32]
PD-165167 DMD0GB4 Schizophrenia 6A20 Preclinical [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [33]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [34]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [35]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [11]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [36]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [37]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [38]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [39]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [40]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [42]
Haloperidol DM96SE0 Delirium Approved [43]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [44]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [45]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [46]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [47]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [48]
Pimozide DMW83TP Schizophrenia 6A20 Approved [49]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [50]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [12]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [51]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [52]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [53]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [11]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [54]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [55]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [56]
Treximet DMU54QB Migraine 8A80 Approved [18]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [15]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [57]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [58]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [59]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [60]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [60]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [61]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [61]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [62]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [5]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [5]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [12]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [64]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [18]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [65]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [66]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [60]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [60]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [8]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [68]
Methotrexate DM2TEOL Anterior urethra cancer Approved [69]
Folic Acid DMEMBJC Colorectal carcinoma Approved [70]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [69]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [69]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [71]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [69]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [72]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(3) dopamine receptor (DRD3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Haloperidol DM96SE0 Delirium Approved [74]
Clozapine DMFC71L Schizophrenia 6A20 Approved [75]
Risperidone DMN6DXL Bipolar I disorder Approved [76]
Folic Acid DMEMBJC Colorectal carcinoma Approved [77]
Methamphetamine DMPM4SK Anxiety Approved [78]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [79]
Droperidol DM0DXA8 Nausea MD90 Approved [80]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [80]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [80]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(4) dopamine receptor (DRD4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [81]
Haloperidol DM96SE0 Delirium Approved [82]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [83]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [84]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [85]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [86]
Methamphetamine DMPM4SK Anxiety Approved [87]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [88]
Droperidol DM0DXA8 Nausea MD90 Approved [80]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By D(2) dopamine receptor (DRD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Droperidol DM0DXA8 Nausea MD90 Approved [80]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [80]
Zuclopenthixol DMKYD5N Schizophrenia 6A20 Approved [80]
Meglitinides DM1OFHN Type-2 diabetes 5A11 Approved [89]
Sulpiride DMF54ZG Schizophrenia 6A20 Approved [90]
Risperidone DMN6DXL Bipolar I disorder Approved [91]
Olanzapine DMPFN6Y Bipolar depression Approved [92]
Methamphetamine DMPM4SK Anxiety Approved [93]
Bromocriptine DMVE3TK Acromegaly 5A60.0 Approved [94]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [95]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [2]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [3]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [4]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Inhibitor [4]
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [5]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [6]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [6]
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Antagonist [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Protein Interaction/Cellular Processes [9]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Protein Interaction/Cellular Processes [10]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Protein Interaction/Cellular Processes [10]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3300).
2 Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem. 1993 Oct 15;36(21):3161-5.
3 Activity of Parthenolide at 5HT2A receptors. J Nat Prod. 1997 Jun;60(6):651-3.
4 Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
5 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
6 Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol. 2000 Jul;130(5):1045-59.
7 Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci Lett. 1995 Feb 17;186(2-3):145-8.
8 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
9 Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins. Eur J Pharmacol. 2011 Jan 15;650(2-3):501-10. doi: 10.1016/j.ejphar.2010.10.023. Epub 2010 Oct 20.
10 Development of a bivalent dopamine D? receptor agonist. J Med Chem. 2011 Nov 24;54(22):7911-9. doi: 10.1021/jm2009919. Epub 2011 Oct 31.
11 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
14 Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
18 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
19 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
20 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
21 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
22 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
23 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
24 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
25 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
26 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
27 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
28 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
29 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
30 Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
32 I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
33 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
34 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
35 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
36 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
37 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
38 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
39 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
40 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
41 Clinical pipeline report, company report or official report of Lundbeck.
42 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
43 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
44 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
45 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
46 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
48 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
49 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
50 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
51 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
52 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
53 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
54 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
55 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
56 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
57 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
58 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
59 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
60 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
61 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
62 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
63 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
64 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
65 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
66 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
67 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
68 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
69 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
70 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
71 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
72 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
73 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
74 The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
75 Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010 Jun;10(3):200-18. doi: 10.1038/tpj.2009.65. Epub 2009 Dec 22.
76 A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J. 2009 Dec;9(6):404-10. doi: 10.1038/tpj.2009.26. Epub 2009 Jun 9.
77 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
78 Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci. 2009 Nov 25;29(47):14734-40. doi: 10.1523/JNEUROSCI.3765-09.2009.
79 Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry. 2009 Oct;166(10):1170-7. doi: 10.1176/appi.ajp.2009.08121801. Epub 2009 Sep 1.
80 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
81 Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005 Nov;115(11):1539-47. doi: 10.1080/00207450590957863.
82 Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
83 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
84 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
85 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
86 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
87 Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):120-4. doi: 10.1002/ajmg.b.30024.
88 Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?. Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 5;144B(8):1034-41. doi: 10.1002/ajmg.b.30540.
89 Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008 Apr;197(2):229-35. doi: 10.1007/s00213-007-1029-z. Epub 2007 Dec 6.
90 Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
91 Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.
92 Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
93 A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
94 Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
95 Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.